Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$7.48B
sum of reported positions
Reported positions
301
Changes vs prior quarter
296
60 new · 37 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 314 measured positions in 8 quarters, the typical new or larger position finished −0.9 pts against the S&P 500 and 47% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 1.96M | $294M | 3.9% | |
| 673K | $292M | 3.9% | |
| 2.15M | $208M | 2.8% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $6.05B | $7.48B |
| Positions | 278 | 301 |
| Biggest line | — | Guardant Health 4% |
| 415K |
| $203M |
| 2.7% |
| 1.25M | $146M | 2.0% |
| 68K | $136M | 1.8% |
| 491K | $132M | 1.8% |
| 599K | $130M | 1.7% |
| 107K | $125M | 1.7% |
| 103K | $117M | 1.6% |
| 126K | $117M | 1.6% |
| 2.11M | $116M | 1.6% |
| 880K | $105M | 1.4% |
| 339K | $101M | 1.3% |
| 6.25M | $98.1M | 1.3% |
| 611K | $93.5M | 1.2% |
| 536K | $90.6M | 1.2% |
| 307K | $89.8M | 1.2% |
| 342K | $89M | 1.2% |
| 252K | $85.7M | 1.1% |
| 728K | $83.9M | 1.1% |
| 1.38M | $80.2M | 1.1% |
| 58K | $79.7M | 1.1% |
| 499K | $79.4M | 1.1% |
| 186K | $79.3M | 1.1% |
Invivyd (IVVD)
9.07M shares in Q1 2026
Adc Therapeutics (ADCT)
5.7M shares in Q1 2026
Evolent Health (EVH)
2.55M shares in Q1 2026
CYBIN INC
1.41M shares in Q1 2026
Global-E Online (GLBE)
1.22M shares in Q1 2026
Cytomx Therapeutics (CTMX)
900K shares in Q1 2026
CENTESSA PHARMACEUTICALS PLC
668K shares in Q1 2026
Corvus Pharmaceuticals (CRVS)
550K shares in Q1 2026
Bridgebio Oncology Therapeutics (BBOT)
541K shares in Q1 2026
Oculis Holding (OCS)
430K shares in Q1 2026
Prologis (PLD)
427K shares in Q1 2026
EQT Corporation (EQT)
400K shares in Q1 2026
Castle Biosciences (CSTL)
386K shares in Q1 2026
Edgewise Therapeutics (EWTX)
150K shares in Q1 2026
EXXON MOBIL CORP
63K shares in Q1 2026
Aurora Innovation (AUR)
37K shares in Q1 2026
Gen Digital (GEN)
35K shares in Q1 2026
ALIGHT INC
19K shares in Q1 2026
Mediaalpha (MAX)
18K shares in Q1 2026
Jfrog (FROG)
17K shares in Q1 2026
Avepoint (AVPT)
15K shares in Q1 2026
American Tower (AMT)
14K shares in Q1 2026
Woodside Energy Group (WDS)
12K shares in Q1 2026
Compass (COMP)
11K shares in Q1 2026
UiPath (PATH)
11K shares in Q1 2026
